Conatus Pharmaceuticals' (CNAT) Price Target Raised to $26 at SunTrust

Stifel Raises price Target on Conatus Pharmaceuticals (CNAT) to $7; Reiterates Buy

Stifel reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT), and raised the price target to $7.00 (from $5.00), following the company's announced option, license and collaboration agreement with Novartis for WW emricasan development and commercialization.

Analyst Stephen Willey commented, "We view the Novartis emricasan collaboration as a... More

Conatus Pharmaceuticals (CNAT) Novartis Deal 'Significantlly' De-risks Emricasan - FBR Capital

FBR Capital analsyt Vernon Bernardino reiterated an Outperform rating and $16 price target on Conatus Pharmaceuticals (NASDAQ: CNAT) after the company announced that it had entered into an exclusive global development and commercialization agreement with NVS for emricasan in multiple liver diseases, including non-alcoholic steatohepatitis (NASH) and liver cirrhosis (LC).

Bernardino "We... More

Conatus Pharmaceuticals (CNAT) PT Raised to $18 at H.C. Wainwright on Novartis Deal

H.C. Wainwright analyst Ed Arce reiterated a Buy rating and raised his price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to $18.00 (from $9.00) after the company announced an exclusive global license and collaboration agreement with Novartis covering emricasan, across all indications, either as a single-agent... More

After-Hours Stock Movers 12/19: (CNAT) (IONS) Higher; (NPTN) (SCMP) (REN) Lower (more...)

Today's After-Hours Movers:

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) 113.8% HIGHER; entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis (NYSE: NVS), Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with... More

Conatus Pharmaceuticals (CNAT) Surges 150% as Trading Resumes Following Novartis Deal

Conatus Pharmaceuticals (NASDAQ: CNAT) surges 155% as trading resumes following a collaboration and license agreement with Novartis.

Conatus Pharmaceuticals (CNAT) to Resume Trading at 5PM ET

Conatus Pharmaceuticals (NASDAQ: CNAT) to Resume Trading at 5PM ET

Conatus Pharmaceuticals (CNAT), Novartis (NVS) Enter Collaboration and License Agreement for Emricasan

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of its first-in-class, orally active pan-caspase inhibitor emricasan with Novartis. Under the terms of the agreement with Novartis (NYSE: NVS), Conatus will receive $50 million upfront, and is eligible to receive $7 million following the exercise of the license option. Conatus can borrow up to $15 million in the form of convertible promissory notes under an investment agreement with Novartis.

Conatus is eligible to receive significant payments if... More